{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:37Z","timestamp":1787019577460,"version":"build-2736575974"},"reference-count":47,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Innovations in immuno-oncology for lymphomas have outpaced therapeutic developments in any other cancer histology. In the 1990s, rituximab, a CD20 monoclonal antibody, drastically changed treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHLs). In parallel, the concept that T cells could be genetically reprogrammed and regulated to address tumor cell evasion was developed. Twenty years later, this concept has materialized\u20143 customized engineered CD19 chimeric antigen receptor T-cell (CART) constructs have been embraced as third-line therapies and beyond for aggressive B-NHL. Responses with CARTs are durable in 30% to 40% of patients, with consistent results in older patients, primary refractory disease, high-grade B-cell lymphoma, and patients with concurrent secondary central nervous system disease, all features historically associated with poorer outcomes. Challenges associated with the administration of CARTs include cumbersome and time-consuming manufacturing processes, toxicities, and cost, not to mention a substantial risk of relapse. Fortunately, as our understanding of how to manipulate the immune system to achieve full antitumor potential has grown, so has the rapid development of off-the-shelf immunotherapies, with CD20\/CD3 bispecific antibodies standing out above all others. These agents have shown promising activity in aggressive B-NHL and have the potential to circumvent some of the challenges encountered with customized engineered products. However, toxicities remain substantial, dosing schedules intensive, and experience limited with these agents. Novel customized and off-the-shelf therapeutics as well as rational combinations of these agents are underway. Ultimately, growing experience with both customized engineered and off-the-shelf immunotherapies will provide guidance on optimal methods of delivery and sequencing.<\/jats:p>","DOI":"10.1182\/hematology.2021000249","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T07:08:54Z","timestamp":1639120134000},"page":"164-173","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Relapsed disease: off-the-shelf immunotherapies vs customized engineered products"],"prefix":"10.1182","volume":"2021","author":[{"given":"Reem","family":"Karmali","sequence":"first","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"6","key":"2021121012064084200_hem2021000249C1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","article-title":"NCCN guidelines insights: B-cell lymphomas, version 3.2019","volume":"17","author":"Zelenetz","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"16","key":"2021121012064084200_hem2021000249C2","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"27","key":"2021121012064084200_hem2021000249C3","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"2021121012064084200_hem2021000249C4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C5","first-page":"40","article-title":"Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-137045","article-title":"Myc expression and tumor-infiltrating T cells are associated with response in patients (Pts) with relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel in the JULIET trial","volume":"136","author":"Jaeger","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2021121012064084200_hem2021000249C7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"2021121012064084200_hem2021000249C8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"2021121012064084200_hem2021000249C9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"2021121012064084200_hem2021000249C10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"2021121012064084200_hem2021000249C11","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2021121012064084200_hem2021000249C12","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"issue":"6","key":"2021121012064084200_hem2021000249C13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"18","key":"2021121012064084200_hem2021000249C14","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-133820","article-title":"Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136044","article-title":"Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"issue":"18","key":"2021121012064084200_hem2021000249C18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a human CD20\u200a\u00d7\u200aCD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2021121012064084200_hem2021000249C20","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2021121012064084200_hem2021000249C21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2021121012064084200_hem2021000249C22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf\u201d allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2021121012064084200_hem2021000249C23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"2021121012064084200_hem2021000249C24","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/bloodadvances.2020003554","article-title":"CAR T cells better than BiTEs","volume":"5","author":"Molina","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2019-126081","article-title":"Earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory large B cell lymphoma","volume":"134","author":"Topp","year":"2019","journal-title":"Blood"},{"issue":"27","key":"2021121012064084200_hem2021000249C26","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"2021121012064084200_hem2021000249C27","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 15","key":"2021121012064084200_hem2021000249C28","doi-asserted-by":"crossref","first-page":"8040","DOI":"10.1200\/JCO.2020.38.15_suppl.8040","article-title":"Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed\/refractory (R\/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): updated results from the PILOT study","volume":"38","author":"Sehgal","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C29","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1182\/blood-2019-123757","article-title":"An individualized risk mitigation approach for safety: experience from the mosunetuzumab (CD20\/CD3 bispecific antibody) development program in relation to neurotoxicity risk","volume":"134","author":"Diefenbach","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136255","article-title":"Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma","volume":"136","author":"Olszewski","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-135818","article-title":"Subcutaneous mosunetuzumab in relapsed or refractory B-cell lymphoma: promising safety and encouraging efficacy in dose escalation cohorts","volume":"136","author":"Matasar","year":"2020","journal-title":"Blood"},{"issue":"47","key":"2021121012064084200_hem2021000249C32","doi-asserted-by":"crossref","first-page":"76902","DOI":"10.18632\/oncotarget.12357","article-title":"T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts","volume":"7","author":"Feucht","year":"2016","journal-title":"Oncotarget"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-136295","article-title":"Mosunetuzumab, a novel CD20\/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2021121012064084200_hem2021000249C34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2020-134449","article-title":"Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL)","volume":"136","author":"Neelapu","year":"2020","journal-title":"Blood"},{"issue":"19","key":"2021121012064084200_hem2021000249C36","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 5","key":"2021121012064084200_hem2021000249C37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/JCO.2018.36.5_suppl.122","article-title":"Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R\/R aggressive B-NHL (TRANSCEND NHL 001 study)","volume":"36","author":"Siddiqi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"22","key":"2021121012064084200_hem2021000249C38","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: the emerging role of CAR-NK cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2021121012064084200_hem2021000249C39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-139868","article-title":"A phase 1, open-label study of MGD013, a bispecific DART\u00ae molecule binding PD-1 and LAG-3 in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"2021121012064084200_hem2021000249C40","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/EDBK_238693","article-title":"Chimeric antigen receptor T-cell therapies for aggressive B-cell lymphomas: current and future state of the art","volume":"39","author":"Abramson","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"12","key":"2021121012064084200_hem2021000249C41","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"1","key":"2021121012064084200_hem2021000249C42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2021121012064084200_hem2021000249C43","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"issue":"20","key":"2021121012064084200_hem2021000249C44","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2021121012064084200_hem2021000249C45","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2141.1999.01608.x","article-title":"Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab","volume":"106","author":"Schmitz","year":"1999","journal-title":"Br J Haematol"},{"issue":"10","key":"2021121012064084200_hem2021000249C46","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"2021121012064084200_hem2021000249C47","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/bloodadvances.2020003531","article-title":"Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial","volume":"5","author":"Abramson","year":"2021","journal-title":"Blood Adv"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/164\/1851658\/164karmali.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/164\/1851658\/164karmali.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T07:09:36Z","timestamp":1639120176000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/164\/482989\/Relapsed-disease-off-the-shelf-immunotherapies-vs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000249","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}